Aethlon Medical (AEMD) Projected to Post Quarterly Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) is expected to announce its Q2 2026 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings results on Wednesday, August 13th. The medical equipment provider reported ($8.50) EPS for the quarter, missing analysts’ consensus estimates of ($6.80) by ($1.70). On average, analysts expect Aethlon Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aethlon Medical Price Performance

Aethlon Medical stock opened at $4.19 on Monday. The firm has a market capitalization of $1.09 million, a price-to-earnings ratio of -0.12 and a beta of 1.83. The company’s 50 day simple moving average is $7.14 and its 200 day simple moving average is $15.46. Aethlon Medical has a fifty-two week low of $4.02 and a fifty-two week high of $84.40.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AEMD shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, October 8th. HC Wainwright reiterated a “neutral” rating on shares of Aethlon Medical in a report on Thursday, August 14th. Finally, Wall Street Zen raised Aethlon Medical to a “sell” rating in a research note on Saturday, August 30th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.